Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Active Immunotherapy with 12-mer Aβ1-42-like Assembly Vaccine Shows Efficacy in Aged 3×Tg-AD Mice

Author(s): Hao Fang, Guo Zhou, Qingli Li, Haichao Wang, Xiaobin Pang, Qing Xu* and Yunzhou Yu*

Volume 21, Issue 1, 2021

Published on: 27 April, 2020

Page: [45 - 55] Pages: 11

DOI: 10.2174/1566524020666200427101231

Price: $65

Abstract

Background: Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder characterized by senile plaques and neurofibrillary tangles (NFTs). The amyloid-oligomer hypothesis indicates that the buildup of toxic oligomers in vivo is likely to impair memory and synaptic function.

Methods: In our study, a kind of novel recombinant chimeric 12×(Aβ1-15-Th) antigen was developed as 12-mer Aβ1-42-like assembly vaccine. We designed this 12×(Aβ1-15- Th) antigen to mimic the assembly states of Aβ1-42 using twelvefold Aβ1–15 (B cell epitopes of human Aβ1-42) and foreign human T helper (Th) epitopes (as the T cell epitopes of Aβ1-42) constructs. Its immunogenicity as a subunit vaccine was tested on C57/BL6 mice, and the efficacy was shown by applying it to AD mice.

Results: This 12×(Aβ1-15-Th) vaccine induced robust Aβ-specific antibodies in 3×Tg- AD and C57/BL6 mice. As early immunotherapeutic agent of AD, the 12×(Aβ1-15-Th) vaccine significantly improved the behavior performance of aged 3 × Tg-AD mice, and reduced the levels of soluble Aβ oligomers and soluble Aβ in the brain. In aged 3 × Tg- AD mice, immunotherapy with the 12×(Aβ1-15-Th) vaccine could prevent Aβ-induced decrease of synaptic proteins, which suggested that it had neuroprotective effects on the brain.

Conclusion: The novel recombinant 12×(Aβ1-15-Th) chimeric vaccine targeting of pathological conformations of Aβ oligomers has shown obvious neuroprotective benefits in the preclinical AD model mouse, which indicates that it is a good candidate vaccine for the prophylaxis of AD.

Keywords: Alzheimer's disease, Amyloid-β, Chimeric vaccine, Immunotherapy, Calpain, Synaptic protein.

« Previous Next »
[1]
Gilbert BJ. The role of amyloid β in the pathogenesis of Alzheimer’s disease. J Clin Pathol 2013; 66(5): 362-6.
[http://dx.doi.org/10.1136/jclinpath-2013-201515] [PMID: 23526599]
[2]
Cummings JG, Lee T. Mortsdorf, A. Ritter, K. Zhong. Alzheimer’s disease drug development pipeline. Alzheimers Dement (N Y) 2017; 3: 367-84.
[http://dx.doi.org/10.1016/j.trci.2017.05.002] [PMID: 29067343]
[3]
Lannfelt L, Relkin NR, Siemers ER. Amyloid-ß-directed immunotherapy for Alzheimer’s disease. J Intern Med 2014; 275(3): 284-95.
[http://dx.doi.org/10.1111/joim.12168] [PMID: 24605809]
[4]
Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol 2014; 10(3): 405-19.
[http://dx.doi.org/10.1586/1744666X.2014.883921] [PMID: 24490853]
[5]
Wisniewski T, Drummond E. Developing therapeutic vaccines against Alzheimer’s disease. Expert Rev Vaccines 2016; 15(3): 401-15.
[http://dx.doi.org/10.1586/14760584.2016.1121815] [PMID: 26577574]
[6]
Martin F, Bachmann Jennings G T. Monique Vogel. A vaccine against Alzheimer`s disease: anything left but faith, expert opinion on biological therapy, 19 2019; 1: 73-8..
[7]
Zahs KR, Ashe KH. β-Amyloid oligomers in aging and Alzheimer’s disease. Front Aging Neurosci 2013; 5: 28.
[http://dx.doi.org/10.3389/fnagi.2013.00028] [PMID: 23847532]
[8]
Hillen H, Barghorn S, Striebinger A, et al. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 2010; 30(31): 10369-79.
[http://dx.doi.org/10.1523/JNEUROSCI.5721-09.2010] [PMID: 20685980]
[9]
Klyubin I, Walsh DM, Lemere CA, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005; 11(5): 556-61.
[http://dx.doi.org/10.1038/nm1234] [PMID: 15834427]
[10]
Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006; 281(7): 4292-9.
[http://dx.doi.org/10.1074/jbc.M511018200] [PMID: 16361260]
[11]
Wang SW, Liu DQ, Zhang LX, et al. A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease. Alzheimers Res Ther 2017; 9(1): 41.
[http://dx.doi.org/10.1186/s13195-017-0267-5] [PMID: 28592267]
[12]
Arndt JW, Qian F, Smith BA, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep 2018; 8(1): 6412.
[http://dx.doi.org/10.1038/s41598-018-24501-0] [PMID: 29686315]
[13]
Budd Haeberlein S, O’Gorman J, Chiao P, et al. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer’s Disease. J Prev Alzheimers Dis 2017; 4(4): 255-63.
[PMID: 29181491]
[14]
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016; 537(7618): 50-6.
[http://dx.doi.org/10.1038/nature19323] [PMID: 27582220]
[15]
Selkoe D J. Alzheimer disease and aducanumab: adjusting our approach Nature reviews 2019; 15-365..
[16]
Abbasi J. Promising Results in 18-Month Analysis of Alzheimer Drug Candidate. JAMA 2018 Sep;; 11320(10): 965.
[17]
Panza F, Lozupone M, Seripa D, Imbimbo BP. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot? Ann Neurol 2019; 85(3): 303-15.
[http://dx.doi.org/10.1002/ana.25410] [PMID: 30635926]
[18]
Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol 2019; 15(2): 73-88.
[http://dx.doi.org/10.1038/s41582-018-0116-6] [PMID: 30610216]
[19]
Yu YZ, Xu Q. Prophylactic immunotherapy of Alzheimer’s disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine. Hum Vaccin Immunother 2016; 12(11): 2801-4.
[http://dx.doi.org/10.1080/21645515.2016.1197456] [PMID: 27379885]
[20]
Agadjanyan MG, Ghochikyan A, Petrushina I, et al. Prototype Alzheimer’s disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174(3): 1580-6.
[http://dx.doi.org/10.4049/jimmunol.174.3.1580] [PMID: 15661919]
[21]
Diethelm-Okita BM, Okita DK, Banaszak L, Conti-Fine BM. Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins. J Infect Dis 2000; 181(3): 1001-9.
[http://dx.doi.org/10.1086/315324] [PMID: 10720523]
[22]
Yu YZ, Wang WB, Chen A, et al. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer’s disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins. J Alzheimers Dis 2014; 41(1): 243-60.
[http://dx.doi.org/10.3233/JAD-132177] [PMID: 24625800]
[23]
Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron 2005; 45(5): 675-88.
[http://dx.doi.org/10.1016/j.neuron.2005.01.040] [PMID: 15748844]
[24]
Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39(3): 409-21.
[http://dx.doi.org/10.1016/S0896-6273(03)00434-3] [PMID: 12895417]
[25]
Yu YZ, Li QL, Wang HC, et al. Improved synaptic and cognitive function in aged 3 × Tg-AD mice with reduced amyloid-β after immunotherapy with a novel recombinant 6Aβ15-TF chimeric vaccine. Clin Immunol 2018; 193: 12-23.
[http://dx.doi.org/10.1016/j.clim.2018.05.005] [PMID: 29803820]
[26]
Wang HC, Yu YZ, Liu S, Zhao M, Xu Q. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer’s disease-like pathology and cognitive decline in aged 3× Tg-AD mice. Vaccine 2016; 34(15): 1758-66.
[http://dx.doi.org/10.1016/j.vaccine.2016.02.056] [PMID: 26945100]
[27]
Czogalla A, Sikorski AF. Spectrin and calpain: a ‘target’ and a ‘sniper’ in the pathology of neuronal cells. Cell Mol Life Sci 2005; 62(17): 1913-24.
[http://dx.doi.org/10.1007/s00018-005-5097-0] [PMID: 15990959]
[28]
Getz GS. Calpain inhibition as a potential treatment of Alzheimer’s disease. Am J Pathol 2012; 181(2): 388-91.
[http://dx.doi.org/10.1016/j.ajpath.2012.04.027] [PMID: 22733009]
[29]
Kelly BL, Ferreira A. beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 2006; 281(38): 28079-89.
[http://dx.doi.org/10.1074/jbc.M605081200] [PMID: 16864575]
[30]
Savioz A, Leuba G, Vallet PG. A framework to understand the variations of PSD-95 expression in brain aging and in Alzheimer’s disease. Ageing Res Rev 2014; 18: 86-94.
[http://dx.doi.org/10.1016/j.arr.2014.09.004] [PMID: 25264360]
[31]
Yu YZ, Liu S, Wang HC, et al. A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer’s Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice. J Neuroimmune Pharmacol 2016; 11(4): 657-68.
[http://dx.doi.org/10.1007/s11481-016-9678-5] [PMID: 27147259]
[32]
Sokolow S, Henkins KM, Bilousova T, et al. AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol Aging 2012; 33(8): 1545-55.
[http://dx.doi.org/10.1016/j.neurobiolaging.2011.05.011] [PMID: 21741125]
[33]
Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Mol Neurodegener 2014; 9: 48.
[http://dx.doi.org/10.1186/1750-1326-9-48] [PMID: 25394486]
[34]
Chen G, Chen KS, Kobayashi D, et al. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci 2007; 27(10): 2654-62.
[http://dx.doi.org/10.1523/JNEUROSCI.3710-06.2007] [PMID: 17344403]
[35]
Movsesyan N, Davtyan H, Mkrtichyan M, et al. Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. Hum Gene Ther 2010; 21(11): 1569-76.
[http://dx.doi.org/10.1089/hum.2009.219] [PMID: 20528468]
[36]
Petrushina I, Ghochikyan A, Mktrichyan M, et al. Alzheimer’s disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci 2007; 27(46): 12721-31.
[http://dx.doi.org/10.1523/JNEUROSCI.3201-07.2007] [PMID: 18003852]
[37]
Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer’s disease and its models. Neuroscience 2013; 251: 51-65.
[http://dx.doi.org/10.1016/j.neuroscience.2012.05.050] [PMID: 22687952]
[38]
Leuba G, Vernay A, Kraftsik R, Tardif E, Riederer BM, Savioz A. Pathological reorganization of NMDA receptors subunits and postsynaptic protein PSD-95 distribution in Alzheimer’s disease. Curr Alzheimer Res 2014; 11(1): 86-96.
[http://dx.doi.org/10.2174/15672050113106660170] [PMID: 24156266]
[39]
Nakanishi N, Ryan SD, Zhang X, et al. Synaptic protein α1-takusan mitigates amyloid-β-induced synaptic loss via interaction with tau and postsynaptic density-95 at postsynaptic sites. J Neurosci 2013; 33(35): 14170-83.
[http://dx.doi.org/10.1523/JNEUROSCI.4646-10.2013] [PMID: 23986251]
[40]
Zhao WQ, Santini F, Breese R, et al. Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J Biol Chem 2010; 285(10): 7619-32.
[http://dx.doi.org/10.1074/jbc.M109.057182] [PMID: 20032460]
[41]
Liu J, Chang L, Roselli F, et al. Amyloid-β induces caspase-dependent loss of PSD-95 and synaptophysin through NMDA receptors. J Alzheimers Dis 2010; 22(2): 541-56.
[http://dx.doi.org/10.3233/JAD-2010-100948] [PMID: 20847396]
[42]
Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease. J Neurosci 2005; 25(40): 9096-101.
[http://dx.doi.org/10.1523/JNEUROSCI.1697-05.2005] [PMID: 16207868]
[43]
Dorostkar MM, Burgold S, Filser S, et al. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model. Brain 2014; 137(Pt 12): 3319-26.
[http://dx.doi.org/10.1093/brain/awu280] [PMID: 25281869]
[44]
Medeiros R, Kitazawa M, Chabrier MA, et al. Calpain inhibitor A-705253 mitigates Alzheimer’s disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol 2012; 181(2): 616-25.
[http://dx.doi.org/10.1016/j.ajpath.2012.04.020] [PMID: 22688056]
[45]
Sinjoanu RC, Kleinschmidt S, Bitner RS, Brioni JD, Moeller A, Ferreira A. The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. Neurochem Int 2008; 53(3-4): 79-88.
[http://dx.doi.org/10.1016/j.neuint.2008.06.003] [PMID: 18590784]
[46]
St-Amour I, Paré I, Tremblay C, Coulombe K, Bazin R, Calon F. IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology. J Neuroinflammation 2014; 11: 54.
[http://dx.doi.org/10.1186/1742-2094-11-54] [PMID: 24655894]

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy